Investment Ratings
-
Master Rating:
-
Gufic Biosciences has an operating revenue of Rs. 721.24 Cr. on a trailing 12-month basis. An annual revenue growth of 28% is outstanding, Pre-tax margin of 12% is healthy, ROE of 25% is exceptional. The company has a reasonable debt to equity of 20%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 32% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 7% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Result Highlights
Gufic BioSciences Ltd Synopsis
NSE-Medical-Generic Drugs
Gufic Biosciences Lt is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 487.70 Cr. and Equity Capital is Rs. 9.69 Cr. for the Year ended 31/03/2021. Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519.-
Market Cap
INR 2,500.21 Cr
-
Sales
INR 721.24 Cr
-
Shares in Float
2.42 Cr
-
No of Funds
10 K
-
Yield
0.04%
-
Book Value
14.42
-
U/D Vol Ratio
1.9
-
LTDebt/Equity
20%
-
Alpha
0.25
-
Beta
1.1
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 65.13% | 65.75% | |
| Mutual Funds | 3.24% | 8.24% | |
| Foreign Portfolio Investors | 0.14% | 0.23% | |
| Financial Institutions/ Banks | 0% | 0% | |
| Individual Investors | 27.67% | 21.92% | |
| Others | 3.82% | 3.86% |
| Name | Designation |
|---|---|
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Mr. Dilip B Ghosh | Whole Time Director |
| Dr. Balram H Singh | Non Exe.Non Ind.Director |
| Mr. Rabi N Sahoo | Independent Director |
| Mr. Gopal M Daptari | Independent Director |
| Mr. Shreyas K Patel | Independent Director |
| Mr. Shrirang V Vaidya | Independent Director |
| Dr. Anu S Auora | Independent Director |
Gufic BioSciences Ltd Forecast
Price Estimates
Eps And Sales Estimates
Gufic BioSciences Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 194.14 | 250.76 | 131.93 | 144.41 | 120.35 |
| Operating Expenses Qtr Cr | 158.31 | 205.11 | 108.18 | 119.94 | 94.72 |
| Operating Profit Qtr Cr | 35.83 | 45.65 | 23.75 | 24.47 | 25.62 |
| Depreciation Qtr Cr | 4.20 | 4.13 | 4.48 | 3.22 | 2.48 |
| Interest Qtr Cr | 1.55 | 1.21 | 2.87 | 3.68 | 3.39 |
| Tax Qtr Cr | 7.05 | 10.33 | 4.18 | 4.99 | 5.68 |
| Net Profit Qtr Cr | 23.34 | 31.21 | 12.87 | 13.18 | 16.33 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 491.43 | 384.63 | 354.94 | 303.91 | 246.96 |
| Operating Expenses Annual Cr | 403.78 | 326.72 | 304.78 | 262.81 | 222.57 |
| Operating Profit Annual in Cr | 83.92 | 52.12 | 45.98 | 38.16 | 22.95 |
| Depreciation Cr | 16.31 | 13.86 | 4.65 | 4.30 | 3.68 |
| Interest Annual Cr | 13.63 | 13.91 | 10.16 | 8.85 | 6.34 |
| Tax Annual Cr | 13.48 | 7.44 | 13.41 | 13.52 | 5.35 |
| Net Profit Annual Cr | 44.23 | 22.69 | 21.94 | 16.02 | 9.02 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 89.06 | 47.10 | 5.21 | -4.85 | -4.13 |
| Cash from Investing Activity Annual Cr | -8.51 | -42.53 | -12.99 | -8.84 | -4.69 |
| Cash from Financing Annual Activity Cr | -78.62 | -4.21 | 7.71 | 14.49 | 7.41 |
| Net Cash Flow Annual Cr | 1.94 | 0.36 | -0.08 | 0.80 | -1.41 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 173.44 | 129.32 | 75.35 | 53.52 | 37.33 |
| Fixed Assets Annual Cr | 113.37 | 113.19 | 34.07 | 24.37 | 22.00 |
| Total Non Current Assets Annual Cr | 131.48 | 134.21 | 47.03 | 39.04 | 35.22 |
| Total Current Assets Annual Cr | 260.58 | 273.31 | 232.51 | 197.04 | 143.25 |
| Total Assets Annual Cr | 392.06 | 407.52 | 279.54 | 236.07 | 178.46 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 17.89 | 13.34 | 9.68 | 6.92 | 4.83 |
| ROE Annual % | 25.50 | 17.54 | 29.11 | 29.93 | 24.16 |
| ROCE Annual % | 31.23 | 26.25 | 48.83 | 53.47 | 41.17 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 17.97 | 15.28 | 14.29 | 13.65 | 9.93 |
Gufic BioSciences Ltd Technicals
EMA & SMA
CURRENT PRICE
257.9 
(3.14)
-
- Bullish Moving Averages 15
- Bearish Moving Averages 1
EMA
-
20 Day
243.31
-
50 Day
224.96
-
100 Day
209.77
-
200 Day
189
Gufic BioSciences Ltd Resistance and support
255.3 PIVOT
-
First Resistance
262.7
-
Second Resistance
275.36
-
Third Resistance
282.75
-
First Support
242.65
-
Second Support
235.25
-
Third Support
222.6
-
RSI
62.99
-
MFI
78.98
-
MACD
12.07
-
MACD signal line
11.73
Gufic BioSciences Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 335,756 | 11,956,271 | 35.61% |
| Week | 490,512 | 19,983,443 | 40.74% |
| 1 Month | 712,384 | 26,913,876 | 37.78% |
| 6 Month | 510,296 | 22,611,205 | 44.31% |
Gufic BioSciences Ltd Price change analysis
49.95
Over 1 month
Low High 195.15 270.1
67.3
Over 3 month
Low High 170.2 270.1
78.85
Over 6 months
Low High 170.2 270.1
135.6
Over Year
Low High 99 270.1Corporate Action
- Board Meeting
| Date | Purpose | Remarks |
|---|---|---|
| 2021-11-03 | Quarterly Results | |
| 2021-08-11 | Quarterly Results | |
| 2021-06-04 | Audited Results & Final Dividend | |
| 2021-02-08 | Quarterly Results | |
| 2020-11-12 | Quarterly Results |
MF Shareholding
| Name | Amount ( in Cr.) |
|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth | 2963.80 |
| SBI Healthcare Opportunities Fund Regular Payout Inc Dist cum Cap Wdrl | 1942.51 |
Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 690.60 | 498.50 (0.38%) | 64032 |
| Lupin Ltd | 1,267.50 | 959.95 (1.85%) | 92145 |
| Suven Life Sciences Ltd | 124.40 | 93.30 (-0.37%) | 23708 |
| Cipla Ltd | 1,005.00 | 895.45 (-0.75%) | 60543 |
News
GUFIC BIOSCIENCES LTD. - 509079 - Statement Of Investor Comp
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor compl Read More
GUFIC BIOSCIENCES LTD. - 509079 - Compliances-Certificate un
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the letter received Read More
GUFIC BIOSCIENCES LTD. - 509079 - Closure of Trading Window
This is to inform you that pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and th Read More
GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulat
In terms of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Read More
GUFIC BIOSCIENCES LTD. - 509079 - Shareholder Meeting / Post
Pursuant to Regulation 30 of the Securities Exchange Board Of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we Read More